These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 10332567)

  • 21. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM; Baus S; Kliesch S; Keck C; Simoni M; Nieschlag E
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progress and prospects in male hormonal contraception.
    Amory JK
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):255-60. PubMed ID: 18438174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone.
    Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C
    J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
    Pangkahila W
    Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiological relationships between inhibin B, follicle stimulating hormone secretion and spermatogenesis in normal men and response to gonadotrophin suppression by exogenous testosterone.
    Anderson RA; Wallace EM; Groome NP; Bellis AJ; Wu FC
    Hum Reprod; 1997 Apr; 12(4):746-51. PubMed ID: 9159436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daily testosterone and gonadotropin levels are similar in azoospermic and nonazoospermic normal men administered weekly testosterone: implications for male contraceptive development.
    Amory JK; Anawalt BD; Bremner WJ; Matsumoto AM
    J Androl; 2001; 22(6):1053-60. PubMed ID: 11700852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Newer agents for hormonal contraception in the male.
    Amory JK; Bremner WJ
    Trends Endocrinol Metab; 2000 Mar; 11(2):61-6. PubMed ID: 10675892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men.
    McLachlan RI; O'Donnell L; Stanton PG; Balourdos G; Frydenberg M; de Kretser DM; Robertson DM
    J Clin Endocrinol Metab; 2002 Feb; 87(2):546-56. PubMed ID: 11836283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
    Meriggiola MC; Bremner WJ; Costantino A; Di Cintio G; Flamigni C
    Hum Reprod; 1998 May; 13(5):1225-9. PubMed ID: 9647551
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress in research into new methods of fertility regulation for men.
    Prog Hum Reprod Res; 1995; (33):2. PubMed ID: 12289975
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) is maintained by TE alone.
    Swerdloff RS; Bagatell CJ; Wang C; Anawalt BD; Berman N; Steiner B; Bremner WJ
    J Clin Endocrinol Metab; 1998 Oct; 83(10):3527-33. PubMed ID: 9768659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of low-dosage oral cyproterone acetate as a male contraceptive.
    Wang C; Yeung KK
    Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of male-fertility-regulating agents.
    Ray S; Verma P; Kumar A
    Med Res Rev; 1991 Sep; 11(5):437-72. PubMed ID: 1943328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido.
    Pavlou SN; Brewer K; Farley MG; Lindner J; Bastias MC; Rogers BJ; Swift LL; Rivier JE; Vale WW; Conn PM
    J Clin Endocrinol Metab; 1991 Dec; 73(6):1360-9. PubMed ID: 1955518
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contraceptive efficacy of a depot progestin and androgen combination in men.
    Turner L; Conway AJ; Jimenez M; Liu PY; Forbes E; McLachlan RI; Handelsman DJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4659-67. PubMed ID: 14557437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive.
    Meriggiola MC; Bremner WJ; Paulsen CA; Valdiserri A; Incorvaia L; Motta R; Pavani A; Capelli M; Flamigni C
    J Clin Endocrinol Metab; 1996 Aug; 81(8):3018-23. PubMed ID: 8768868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of testosterone substitution on sperm suppression by LHRH agonists.
    Bouchard P; Garcia E
    Horm Res; 1987; 28(2-4):175-80. PubMed ID: 2969861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug insight: Recent advances in male hormonal contraception.
    Amory JK; Page ST; Bremner WJ
    Nat Clin Pract Endocrinol Metab; 2006 Jan; 2(1):32-41. PubMed ID: 16932251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sperm motion parameters after suppression of spermatogenesis with a gonadotropin-releasing hormone antagonist plus testosterone supplementation.
    Bastias MC; Kamijo H; Pavlou SN
    Fertil Steril; 1993 Jun; 59(6):1261-5. PubMed ID: 8495775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GnRH analogues for contraception.
    Fraser HM
    Br Med Bull; 1993 Jan; 49(1):62-72. PubMed ID: 8324616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.